Sagefield Capital LP Tcr2 Therapeutics Inc. Transaction History

Sagefield Capital LP

  • $769 Million
  • Q1 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$1.0 - $1.62 $43,900 - $71,118
43,900 New
43,900 $65,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Sagefield Capital LP Portfolio

Follow Sagefield Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sagefield Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Sagefield Capital LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email